Abstract views : 177 ; PDF downloads : 23

Main Article Content

Aditi Kundoo
Sabina Langer
Divij Sachdeva
Anupam Sachdeva
Jyoti Kotwal

Abstract

Hematogone hyperplasia is seen in many reactive and neoplastic conditions such as autoimmune cytopenia(s), post viral infections, Hodgkin/ Non Hodgkin lymphoma, acute myeloid leukaemia, post chemotherapy or stem cell transplant bone marrow. However, occasionally a marked reactive process like hematogone hyperplasia can mask an important underlying morphology. It is further compounded in cases where the diagnostic cells are few in number. Clinching a diagnosis in such cases becomes increasingly difficult.

Keywords:
hematogone hyperplasia, flowcytometric, bone marrow biopsy

Article Details

How to Cite
Kundoo, Aditi, Sabina Langer, Divij Sachdeva, Anupam Sachdeva, and Jyoti Kotwal. 2020. “Hematogone Hyperplasia - A Double Edged Sword”. Current Cancer Reports 3 (1), 64-67. https://doi.org/10.25082/CCR.2021.01.001.
Section
Correspondence

References

[1] McKenna RW, Washington LT, Aquino DB, et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood, 2001, 98(8): 2498-2507. https://doi.org/10.1182/blood.V98.8.2498
[2] Chantepie SP, Cornet E, Sala¨un V, et al. Hematogones: an overview. Leukemia Research, 2013, 37(11): 1404-1411. https://doi.org/10.1016/j.leukres.2013.07.024
[3] Richard G, Brody J and Sun T. A case of acute megakaryocytic leukemia with hematogones. Leukemia, 1993, 7(11): 1900-1903.
[4] Anton-Harisi M, Douna V, Baka M, et al. Acute megakaryoblastic leukemia with increased hematogones in children. Journal of Pediatric Hematology/Oncology, 2012, 34(8): e337-e340. https://doi.org/10.1097/MPH.0b013e3182678ddb
[5] Chaudhari J, Borges A, Bansal S, et al. AML M7 Misdiagnosed as ALL. Indian Journal of Hematology and Blood Transfusion, 2014, 30(Suppl 1): 199-201. https://doi.org/10.1007/s12288-013-0326-4
[6] Rack KA, van den Berg E, Haferlach C, et al. European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms. Leukemia, 2019, 33(8): 1851-1867. https://doi.org/10.1038/s41375-019-0378